{"id":"experimental-recombinant-hepatitis-b-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant hepatitis B surface antigen (HBsAg) produced through genetic engineering, typically in yeast or mammalian cell systems. Upon administration, it triggers both humoral (antibody-mediated) and cellular immune responses, leading to the production of anti-HBs antibodies and memory B cells that protect against subsequent exposure to hepatitis B virus.","oneSentence":"This recombinant hepatitis B vaccine stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen, providing protection against hepatitis B infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:43.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B infection in unvaccinated or non-immune populations"}]},"trialDetails":[{"nctId":"NCT03038802","phase":"PHASE1, PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":"Chronic Hepatitis b","enrollment":40},{"nctId":"NCT04723602","phase":"PHASE1","title":"Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2021-01-06","conditions":"Ebola Virus Disease, Marburg Virus Disease","enrollment":32},{"nctId":"NCT04075201","phase":"PHASE1","title":"Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2019-07-07","conditions":"Hepatitis B","enrollment":144},{"nctId":"NCT00414050","phase":"PHASE3","title":"A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Hepatitis B","enrollment":1718},{"nctId":"NCT00440531","phase":"PHASE3","title":"Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11","conditions":"Hepatitis B","enrollment":540},{"nctId":"NCT00551629","phase":"PHASE2","title":"A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-05","conditions":"Bacterial Infections; Virus Diseases","enrollment":708},{"nctId":"NCT00092469","phase":"PHASE3","title":"Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":151},{"nctId":"NCT00500747","phase":"PHASE1","title":"Chiron Corp HCV E1/E2 Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-08","conditions":"Hepatitis C","enrollment":60},{"nctId":"NCT01183611","phase":"PHASE3","title":"The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2007-04","conditions":"Virus Disease, DNA Virus Infections, Hepadnaviridae Infections","enrollment":1740},{"nctId":"NCT00697840","phase":"PHASE3","title":"Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1995-06","conditions":"Hepatitis B","enrollment":150},{"nctId":"NCT00697125","phase":"PHASE2","title":"Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1993-06","conditions":"Hepatitis B","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental recombinant hepatitis B vaccine","genericName":"Experimental recombinant hepatitis B vaccine","companyName":"Jiangsu Province Centers for Disease Control and Prevention","companyId":"jiangsu-province-centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"This recombinant hepatitis B vaccine stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen, providing protection against hepatitis B infection. Used for Prevention of hepatitis B infection in unvaccinated or non-immune populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}